PATTI SPARLING: Open Payments
NPI 1720121825 · FRANKLIN, NC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,467 in 127 payments from 24 companies in 2025. Trend: 2023 $2,199 · 2024 $2,483 · 2025 $2,467
Food & beverage: $2,467
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 25 | $420 |
| Vanda Pharmaceuticals Inc. | 10 | $268 |
| AstraZeneca Pharmaceuticals LP | 13 | $253 |
| Novo Nordisk Inc | 11 | $248 |
| Otsuka America Pharmaceutical, Inc. | 6 | $196 |
| Amgen Inc. | 12 | $181 |
| Lilly USA, LLC | 8 | $136 |
| GlaxoSmithKline, LLC. | 5 | $94 |
| Bayer Healthcare Pharmaceuticals Inc. | 5 | $85 |
| Viatris Specialty LLC | 4 | $78 |
Products named: VRAYLAR, FANAPT, REXULTI, Ozempic, TRELEGY ELLIPTA, Kerendia, JARDIANCE, YUPELRI.
Industry payments across NC — which companies pay providers there.
